Q&A With Gilmore O'Neill of Biogen International: Continuing to Learn About Multiple Sclerosis Treatment

Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.

Gilmore O'Neill, MD, of Biogen international looked at what steps are taken when developing new medications and what they look for as patients have different needs during the course of their treatment during the American Academy of Neurology's annual meeting in Washington DC.